Acute	acute	O	O
changes	changes	O	O
of	of	O	O
blood	blood	O	O
ammonia	ammonia	O	O
may	may	O	O
predict	predict	O	O
short-term	short-term	O	O
adverse	adverse	O	O
effects	effects	O	O
of	of	O	O
valproic	valproic	B_chemical	O
acid	acid	I_chemical	O
.	.	O	O

Valproic	valproic	B_chemical	O
acid	acid	I_chemical	O
(	(	O	O
VPA	vpa	S_chemical	O
)	)	O	O
was	was	O	O
given	given	O	O
to	to	O	O
24	24	O	O
epileptic	epileptic	O	S_disease
patients	patients	O	O
who	who	O	O
were	were	O	O
already	already	O	O
being	being	O	O
treated	treated	O	O
with	with	O	O
other	other	O	O
antiepileptic	antiepileptic	O	O
drugs	drugs	O	O
.	.	O	O

A	a	O	O
standardized	standardized	O	O
loading	loading	O	O
dose	dose	O	O
of	of	O	O
VPA	vpa	S_chemical	O
was	was	O	O
administered	administered	O	O
,	,	O	O
and	and	O	O
venous	venous	O	O
blood	blood	O	O
was	was	O	O
sampled	sampled	O	O
at	at	O	O
0	0	O	O
,	,	O	O
1	1	O	O
,	,	O	O
2	2	O	O
,	,	O	O
3	3	O	O
,	,	O	O
and	and	O	O
4	4	O	O
hours	hours	O	O
.	.	O	O

Ammonia	ammonia	O	O
(	(	O	O
NH3	nh3	O	O
)	)	O	O
was	was	O	O
higher	higher	O	O
in	in	O	O
patients	patients	O	O
who	who	O	O
,	,	O	O
during	during	O	O
continuous	continuous	O	O
therapy	therapy	O	O
,	,	O	O
complained	complained	O	O
of	of	O	O
drowsiness	drowsiness	O	O
(	(	O	O
7	7	O	O
patients	patients	O	O
)	)	O	O
than	than	O	O
in	in	O	O
those	those	O	O
who	who	O	O
were	were	O	O
symptom-free	symptom-free	O	O
(	(	O	O
17	17	O	O
patients	patients	O	O
)	)	O	O
,	,	O	O
although	although	O	O
VPA	vpa	S_chemical	O
plasma	plasma	O	O
levels	levels	O	O
were	were	O	O
similar	similar	O	O
in	in	O	O
both	both	O	O
groups	groups	O	O
.	.	O	O

By	by	O	O
measuring	measuring	O	O
VPA-induced	vpa-induced	O	O
changes	changes	O	O
of	of	O	O
blood	blood	O	O
NH3	nh3	O	O
content	content	O	O
,	,	O	O
it	it	O	O
may	may	O	O
be	be	O	O
possible	possible	O	O
to	to	O	O
identify	identify	O	O
patients	patients	O	O
at	at	O	O
higher	higher	O	O
risk	risk	O	O
of	of	O	O
obtundation	obtundation	O	O
when	when	O	O
VPA	vpa	S_chemical	O
is	is	O	O
given	given	O	O
chronically	chronically	O	O
.	.	O	O

